Chemspace | Building Blocks for Analogs of Infigratinib

Warning!
Your browser does not support JavaScript or JavaScript support is disabled.
Display of the content may be incorrect. Please make sure that JavaScript is enabled in your browser. Warning!
Apparently you are using proxy server to access this site.
It means that display of the content may be incorrect.

Warning!
Your browser does not support HTML5.
Display of the content may be incorrect. Please make sure that your browser supports HTML5 syntax.

Home News Building Blocks for Analogs of Infigratinib

1 June 2021

Building Blocks for Analogs of Infigratinib

This May, Infigratinib (TRUSELTIQ) received approval by the FDA for adults treatment of cholangiocarcinoma.

It is an ATP-competitive, fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3) tyrosine kinase inhibitor implicated in origin of FGFR-driven diseases.

Infigratinib contains dihalogen dimethoxy aniline moiety in its backbone.

We have made a set of Building Blocks, which contain similar parts – the perfect start for your research!

Building Blocks for Analogs of Infigratinib

Enquire for x () from in

Enquire for

Would you like to submit a custom request?

Enquiry for a list of compounds

Please select the ship to country:

Sign in